LTRN Lantern Pharma Inc. - 8-K

Item
7.01 Regulation FD Disclosure.

On
June 1, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s discussions
regarding the Harmonic™ Phase 2 clinical trial for the Company’s product candidate known as LP-300.

A
copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The
information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item
9.01 Financial Statements and Exhibits.

(d)
Exhibits .

Exhibit
No.

Exhibit
Description

99.1

Presentation relating to June 1, 2026 discussions regarding the Harmonic™ LP-300 Phase 2 clinical trial.

104

Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

2